These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10381072)

  • 1. Anti-M protein antibody in post-streptococcal reactive arthritis.
    Maeno N; Yoshinaga M; Takei S; Nishi J; Imanaka H; Wahid MR; Sameshima K; Miyata K
    J Rheumatol; 1999 Jun; 26(6):1417-9. PubMed ID: 10381072
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidemiologic profile of streptococcal infections in collectivities of children followed over a sixteen year period.
    Măgureanu E; Dobrescu A; Horhogea G; Ulmeanu V; Grigoriu T; Debeleac L; Ionescu M; Ionescu E; Zolotovschi JC
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):375-84. PubMed ID: 6761392
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccination of pony foals with M-like protein of Streptococcus equi.
    Srivastava SK; Barnum DA
    Am J Vet Res; 1983 Jan; 44(1):41-5. PubMed ID: 6824223
    [No Abstract]   [Full Text] [Related]  

  • 4. Determination of group a streptococcal anti-M type-specific antibody in sera of rheumatic fever patients after 45 years.
    Bencivenga JF; Johnson DR; Kaplan EL
    Clin Infect Dis; 2009 Oct; 49(8):1237-9. PubMed ID: 19761409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response to superoxide dismutase in group A streptococcal infection.
    McMillan DJ; Davies MR; Good MF; Sriprakash KS
    FEMS Immunol Med Microbiol; 2004 Apr; 40(3):249-56. PubMed ID: 15039102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
    Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
    Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between elevated serum antibody levels to streptococcal M12 protein and susceptibility to dermatomyositis.
    Ichimiya M; Yasui H; Hirota Y; Ohmura A; Muto M
    Arch Dermatol Res; 1998 Apr; 290(4):229-30. PubMed ID: 9617445
    [No Abstract]   [Full Text] [Related]  

  • 8. Protective antibody against a peptide fragment of type 5 streptococcal M protein cross-reacts with human heart tissue.
    Dale JB; Beachey EH
    Trans Assoc Am Physicians; 1982; 95():286-91. PubMed ID: 7182981
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibodies to streptococcal inhibitor of complement function and M peptides in a post-streptococcal glomerulonephritis endemic region of Australia.
    Sriprakash KS; Hartas J; White A
    J Med Microbiol; 2002 Jul; 51(7):589-650. PubMed ID: 12132776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
    Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics.
    Hoe NP; Kordari P; Cole R; Liu M; Palzkill T; Huang W; McLellan D; Adams GJ; Hu M; Vuopio-Varkila J; Cate TR; Pichichero ME; Edwards KM; Eskola J; Low DE; Musser JM
    J Infect Dis; 2000 Nov; 182(5):1425-36. PubMed ID: 11015234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fc-receptor proteins of Streptococcus pyogenes and pathogenesis of post-infection complications].
    Totolian AA; Burova LA
    Zh Mikrobiol Epidemiol Immunobiol; 2014; (3):78-90. PubMed ID: 25286515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for a group A streptococcal vaccine.
    McMillan DJ; Chhatwal GS
    Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of predominant bacterial antigens triggering antibody response in Salmonella reactive arthritis: apropos of a case.
    Lacoste MG; Cargnelutti DE; Tamashiro H; Di Genaro MS
    Jpn J Infect Dis; 2007 Jul; 60(4):220-4. PubMed ID: 17642539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Further study of the prevention of streptococcal infections in experiments on monkeys].
    Keller V; Dzhikidze EK; Voskanian NA; Kiunemund O; Knol' G
    Vestn Akad Med Nauk SSSR; 1986; (3):66-8. PubMed ID: 3518270
    [No Abstract]   [Full Text] [Related]  

  • 16. Group A streptococcus epidemiology and vaccine implications.
    Cohen-Poradosu R; Kasper DL
    Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
    [No Abstract]   [Full Text] [Related]  

  • 17. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity to group a streptococcal M proteins: forging a single-edged sword.
    Madoff LC
    Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
    [No Abstract]   [Full Text] [Related]  

  • 19. Acquisition of group A streptococcal M protein antibodies.
    Quinn RW; Vander Zwaag R; Lowry PN
    Pediatr Infect Dis; 1985; 4(4):374-8. PubMed ID: 3895177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-streptococcal antibodies in the diagnosis of acute and post-streptococcal disease: streptokinase versus streptolysin O and deoxyribonuclease B.
    Blyth CC; Robertson PW
    Pathology; 2006 Apr; 38(2):152-6. PubMed ID: 16581656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.